Literature DB >> 18753195

In vitro and in vivo properties of adenovirus vectors with increased affinity to CD46.

Hongjie Wang1, Ying Liu, Zongyi Li, Sebastian Tuve, Daniel Stone, Oleksandr Kalyushniy, Dmitry Shayakhmetov, Christophe L M Verlinde, Thilo Stehle, John McVey, Andrew Baker, Kah-Whye Peng, Steve Roffler, André Lieber.   

Abstract

Gene transfer vectors containing adenovirus (Ad) serotype 35 (Ad35) fibers have shown promise for cancer and stem cell gene therapy. In this study, we attempted to improve the in vitro and in vivo infection properties of these vectors by increasing their affinity to the Ad35 fiber receptor CD46. We constructed Ad vectors containing either the wild-type Ad35 fiber knob (Ad5/35) or Ad35 knob mutants with 4-fold- and 60-fold-higher affinity to CD46 (Ad5/35+ and Ad5/35++, respectively). In in vitro studies with cell lines, the higher affinities of Ad5/35+ and Ad5/35++ to CD46 did not translate into correspondingly higher transduction efficiencies, regardless of the CD46 receptor density present on cells. However, in vivo, in a mouse model with preestablished CD46(high) liver metastases, intravenous injection of Ad5/35++ resulted in more-efficient tumor cell transduction. We conclude that Ad5/35 vectors with increased affinity to CD46 have an advantage in competing with non-CD46-mediated sequestration of vector particles after intravenous injection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18753195      PMCID: PMC2573189          DOI: 10.1128/JVI.01308-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

Review 1.  Complex target SELEX.

Authors:  Steven M Shamah; Judith M Healy; Sharon T Cload
Journal:  Acc Chem Res       Date:  2008-01       Impact factor: 22.384

2.  Abrupt emergence of diverse species B adenoviruses at US military recruit training centers.

Authors:  David Metzgar; Miguel Osuna; Adriana E Kajon; Anthony W Hawksworth; Marina Irvine; Kevin L Russell
Journal:  J Infect Dis       Date:  2007-10-31       Impact factor: 5.226

3.  Downregulation of human CD46 by adenovirus serotype 35 vectors.

Authors:  F Sakurai; K Akitomo; K Kawabata; T Hayakawa; H Mizuguchi
Journal:  Gene Ther       Date:  2007-03-22       Impact factor: 5.250

4.  Modification of adenovirus capsid with a designed protein ligand yields a gene vector targeted to a major molecular marker of cancer.

Authors:  Natalya Belousova; Galina Mikheeva; Juri Gelovani; Victor Krasnykh
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

5.  Affinity thresholds for membrane fusion triggering by viral glycoproteins.

Authors:  Kosei Hasegawa; Chunling Hu; Takafumi Nakamura; James D Marks; Stephen J Russell; Kah-Whye Peng
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

6.  Identification of CD46 binding sites within the adenovirus serotype 35 fiber knob.

Authors:  Hongjie Wang; Yen-Chywan Liaw; Daniel Stone; Oleksandr Kalyuzhniy; Imameddin Amiraslanov; Sebastian Tuve; Christophe L M J Verlinde; Dmitry Shayakhmetov; Thilo Stehle; Steve Roffler; André Lieber
Journal:  J Virol       Date:  2007-09-26       Impact factor: 5.103

7.  Interaction of penton base Arg-Gly-Asp motifs with integrins is crucial for adenovirus serotype 35 vector transduction in human hematopoietic cells.

Authors:  S Murakami; F Sakurai; K Kawabata; N Okada; T Fujita; A Yamamoto; T Hayakawa; H Mizuguchi
Journal:  Gene Ther       Date:  2007-09-06       Impact factor: 5.250

8.  Transduction properties of adenovirus serotype 35 vectors after intravenous administration into nonhuman primates.

Authors:  Fuminori Sakurai; Shin-ichiro Nakamura; Kimiyo Akitomo; Hiroaki Shibata; Keiji Terao; Kenji Kawabata; Takao Hayakawa; Hiroyuki Mizuguchi
Journal:  Mol Ther       Date:  2008-03-11       Impact factor: 11.454

9.  Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression.

Authors:  Zejing Wang; Christian S Kuhr; James M Allen; Michael Blankinship; Paul Gregorevic; Jeffrey S Chamberlain; Stephen J Tapscott; Rainer Storb
Journal:  Mol Ther       Date:  2007-04-10       Impact factor: 11.454

10.  Adenovirus serotype 5 hexon mediates liver gene transfer.

Authors:  Simon N Waddington; John H McVey; David Bhella; Alan L Parker; Kristeen Barker; Hideko Atoda; Rebecca Pink; Suzanne M K Buckley; Jenny A Greig; Laura Denby; Jerome Custers; Takashi Morita; Ivo M B Francischetti; Robson Q Monteiro; Dan H Barouch; Nico van Rooijen; Claudio Napoli; Menzo J E Havenga; Stuart A Nicklin; Andrew H Baker
Journal:  Cell       Date:  2008-02-08       Impact factor: 41.582

View more
  35 in total

1.  Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors.

Authors:  Raul Alba; Angela C Bradshaw; Lynda Coughlan; Laura Denby; Robert A McDonald; Simon N Waddington; Suzanne M K Buckley; Jenny A Greig; Alan L Parker; Ashley M Miller; Hongjie Wang; Andre Lieber; Nico van Rooijen; John H McVey; Stuart A Nicklin; Andrew H Baker
Journal:  Blood       Date:  2010-07-07       Impact factor: 22.113

Review 2.  Protein engineering to target complement evasion in cancer.

Authors:  Darrick Carter; André Lieber
Journal:  FEBS Lett       Date:  2013-11-14       Impact factor: 4.124

3.  Her2-specific multivalent adapters confer designed tropism to adenovirus for gene targeting.

Authors:  Birgit Dreier; Galina Mikheeva; Natalya Belousova; Petra Parizek; Edgar Boczek; Ilian Jelesarov; Patrik Forrer; Andreas Plückthun; Victor Krasnykh
Journal:  J Mol Biol       Date:  2010-11-05       Impact factor: 5.469

Review 4.  A novel fiber chimeric conditionally replicative adenovirus-Ad5/F35 for tumor therapy.

Authors:  Ming Yang; Chun Sheng Yang; WenWen Guo; JianQin Tang; Qian Huang; ShouXin Feng; AiJun Jiang; XiFeng Xu; Guan Jiang; Yan Qun Liu
Journal:  Cancer Biol Ther       Date:  2017-11-16       Impact factor: 4.742

5.  Single-dose MGTA-145/plerixafor leads to efficient mobilization and in vivo transduction of HSCs with thalassemia correction in mice.

Authors:  Chang Li; Kevin A Goncalves; Tamás Raskó; Amit Pande; Sucheol Gil; Zhinan Liu; Zsuzsanna Izsvák; Thalia Papayannopoulou; John C Davis; Hans-Peter Kiem; André Lieber
Journal:  Blood Adv       Date:  2021-03-09

Review 6.  In Vivo Hematopoietic Stem Cell Transduction.

Authors:  Maximilian Richter; Daniel Stone; Carol Miao; Olivier Humbert; Hans-Peter Kiem; Thalia Papayannopoulou; André Lieber
Journal:  Hematol Oncol Clin North Am       Date:  2017-10       Impact factor: 3.722

7.  Avidity binding of human adenovirus serotypes 3 and 7 to the membrane cofactor CD46 triggers infection.

Authors:  Hung V Trinh; Guillaume Lesage; Venus Chennamparampil; Benedikt Vollenweider; Christoph J Burckhardt; Stefan Schauer; Menzo Havenga; Urs F Greber; Silvio Hemmi
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

8.  Prophylactic In Vivo Hematopoietic Stem Cell Gene Therapy with an Immune Checkpoint Inhibitor Reverses Tumor Growth in Syngeneic Mouse Tumor Models.

Authors:  Chang Li; Meredith M Course; Iain A McNeish; Charles W Drescher; Paul N Valdmanis; André Lieber
Journal:  Cancer Res       Date:  2019-11-14       Impact factor: 12.701

9.  A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy.

Authors:  Hongjie Wang; Ying Liu; Zong-Yi Li; Xiaolong Fan; Akseli Hemminki; André Lieber
Journal:  Blood       Date:  2009-11-12       Impact factor: 22.113

10.  Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors.

Authors:  Jenny A Greig; Suzanne Mk Buckley; Simon N Waddington; Alan L Parker; David Bhella; Rebecca Pink; Ahad A Rahim; Takashi Morita; Stuart A Nicklin; John H McVey; Andrew H Baker
Journal:  Mol Ther       Date:  2009-07-14       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.